See more : Eureka Forbes Limited (EUREKAFORBE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Toshiba Corporation (0Q0C.L) Income Statement Analysis – Financial Results
- Shyama Infosys Limited (SHYAMAINFO.BO) Income Statement Analysis – Financial Results
- Lake Area Corn Processors, LLC (LKCRU) Income Statement Analysis – Financial Results
- Jenscare Scientific Co., Ltd. (9877.HK) Income Statement Analysis – Financial Results
- Thai Stanley Electric Public Company Limited (STANLY.BK) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports